Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | BAG3 | O95817 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816958 | 1.00 | PPARG (0.66) | PPARGMAPK1MAOAMAOBMEN1 | |
| SCHEMBL21783184 | 0.89 | PPARG (0.83) | PPARGMAPK1MAOAMAOBMEN1 | |
| SCHEMBL15817056 | 0.85 | CA9 (0.78) | PPARGMAPK1MAOAMAOBAKR1B1 | |
| SCHEMBL15817052 | 0.85 | CA9 (0.78) | PPARGMAPK1MAOAMAOBAKR1B1 | |
| SCHEMBL15817054 | 0.85 | CA9 (0.78) | PPARGMAPK1MAOAMAOBAKR1B1 | |
| SCHEMBL15816246 | 0.82 | PTPN1 (0.62) | MAPK1MAOAMAOBMEN1POLB | |
| SCHEMBL15816243 | 0.82 | PTPN1 (0.62) | MAPK1MAOAMAOBMEN1POLB | |
| SCHEMBL15818349 | 0.80 | MAPK1 (0.83) | PPARGMAPK1MAOAMAOBCA9 | |
| SCHEMBL15818347 | 0.80 | MAPK1 (0.83) | PPARGMAPK1MAOAMAOBCA9 | |
| SCHEMBL15818348 | 0.80 | MAPK1 (0.83) | PPARGMAPK1MAOAMAOBCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115122-B2 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | PPARG 4425/4885MAPK1 1/4885MAOA 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.